Press coverage about ChemoCentryx (NASDAQ:CCXI) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ChemoCentryx earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 47.4597542705055 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- ChemoCentryx Inc (CCXI) Given $13.00 Consensus Price Target by Analysts (americanbankingnews.com)
- ChemoCentryx (CCXI) PT Raised to $16.00 at JPMorgan Chase & Co. (americanbankingnews.com)
- Active Stock Evaluation – ChemoCentryx Inc (NASDAQ: CCXI) – Alpha Beta Stock (alphabetastock.com)
- ChemoCentryx, Inc. (CCXI) : Keep an eye on Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Mar 12, 2018 – ChemoCentryx Inc (CCXI) Files 10-K for the Fiscal … – GuruFocus.com (gurufocus.com)
Several equities analysts have commented on CCXI shares. BidaskClub raised ChemoCentryx from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 3rd. JPMorgan Chase & Co. increased their price target on ChemoCentryx from $13.00 to $16.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $12.13.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $1.02. The firm had revenue of $56.30 million for the quarter, compared to the consensus estimate of $9.03 million. equities analysts anticipate that ChemoCentryx will post -1.25 earnings per share for the current year.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.